News - saxagliptin, Bristol-Myers Squibb


Popular Filters

FDA probes possible higher risk of pancreatitis for newer type 2 diabetes drugs


The US Food and Drug Administration revealed in a web posting yesterday that it is evaluating unpublished…

Boehringer IngelheimBristol-Myers SquibbDiabetesEli LillyExenatide InjectionlinagliptinMerck & CoNorth AmericaNovo NordiskPharmaceuticalRegulationsaxagliptinsitagliptinVictoza

Germany's IQWiG finds no added benefit for Komboglyze or for Pixuvri


In an early benefit assessment under Germany's Act on the Reform of the Market for Medicinal Products…

AstraZenecaBiotechnologyBristol-Myers SquibbCell TherapeuticsDiabetesEuropeKomboglyzemetforminOncologyPharmaceuticalPixuvriPricingRegulationsaxagliptin

Otsuka sells on Japanese saxagliptin rights to Kyowa Hakko


Japanese drugmakers Otsuka Pharmaceutical (TYO: 4578) and Kyowa Hakko Kirin (TYO: 4151) have entered…

Asia-PacificBristol-Myers SquibbDiabetesKyowa Hakko KirinLicensingOncologyOtsukaPharmaceuticalResearchsaxagliptin

Back to top